Mediwound Ltd (MDWD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mediwound Ltd (MDWD) has a cash flow conversion efficiency ratio of -0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($59.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MDWD net asset quality index to measure how much of total assets are equity-financed.
Mediwound Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Mediwound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mediwound Ltd (MDWD) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Mediwound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mediwound Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuen Chaang Uppertech
TWO:6265
|
-0.047x |
|
Kao Hsiung Chang Iron & Steel Corp
TW:2008
|
-0.001x |
|
Finance of America Companies Inc
NYSE:FOA
|
-0.209x |
|
Consumer Portfolio Services Inc
NASDAQ:CPSS
|
0.276x |
|
The Reject Shop Ltd
AU:TRS
|
0.447x |
|
Loncor Resources Inc
TO:LN
|
-0.046x |
|
inTest Corporation
NYSE MKT:INTT
|
-0.010x |
|
Exacompta Clairefontaine
PA:ALEXA
|
0.200x |
Annual Cash Flow Conversion Efficiency for Mediwound Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mediwound Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Mediwound Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.15 Million | $-13.62 Million | -0.437x | -32.03% |
| 2023-12-31 | $31.59 Million | $-10.46 Million | -0.331x | +69.58% |
| 2022-12-31 | $10.91 Million | $-11.88 Million | -1.089x | -155.96% |
| 2021-12-31 | $-4.58 Million | $-8.92 Million | 1.946x | +305.23% |
| 2020-12-31 | $7.27 Million | $-6.89 Million | -0.948x | -273.51% |
| 2019-12-31 | $15.17 Million | $8.29 Million | 0.546x | +140.34% |
| 2018-12-31 | $8.97 Million | $-12.15 Million | -1.355x | +20.80% |
| 2017-12-31 | $9.62 Million | $-16.45 Million | -1.710x | +19.18% |
| 2016-12-31 | $7.77 Million | $-16.45 Million | -2.116x | -153.42% |
| 2015-12-31 | $23.47 Million | $-19.60 Million | -0.835x | -117.08% |
| 2014-12-31 | $42.87 Million | $-16.49 Million | -0.385x | -178.22% |
| 2013-12-31 | $-19.80 Million | $-9.74 Million | 0.492x | +262.63% |
| 2012-12-31 | $15.63 Million | $-4.73 Million | -0.302x | -- |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more